Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
apomorphine infusion · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Apomorphine infusion | EXPERIMENTAL | Continuous subcutaneous apomorphine infusion |
| Name | Type | Description |
|---|---|---|
| apomorphine infusion | DRUG | Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device |
Inclusion Criteria: * Advanced idiopathic PD consistent with UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria * Overall motor control is unsatisfactory in the opinion of the Investigator and subject despite optimized treatment with available therapies, which must include a sta...
Apomorphine infusion is used for the treatment of idiopathic Parkinson's Disease. It is a small molecule therapy being developed by Supernus Pharmaceuticals, Inc. (SUPN). The drug is currently in Phase 3 clinical development and is intended to address symptoms associated with this neurological condition.
Apomorphine infusion is a small molecule that acts as a dopamine receptor agonist. It works by stimulating dopamine receptors in the brain, which helps to compensate for the loss of dopamine-producing neurons that occurs in Parkinson's disease. This mechanism helps to alleviate motor symptoms associated with the condition.
Apomorphine infusion is being developed by Supernus Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SUPN. The company is conducting clinical trials to evaluate the safety and efficacy of this drug for the treatment of idiopathic Parkinson's Disease.
Apomorphine infusion is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is designed to assess the long-term safety of the infusion in patients with idiopathic Parkinson's Disease.
Apomorphine infusion is being studied in a Phase 3 clinical trial with the identifier NCT02339064, titled 'Infusion of Apomorphine: Long-term Safety Study'. This active, non-recruiting trial has an enrollment of 99 participants and is being conducted in the United States. The study is open to adults aged 30 years and older.
Apomorphine infusion is a formulation of apomorphine, a dopamine receptor agonist, delivered via continuous infusion. While apomorphine is the active pharmaceutical ingredient, the infusion formulation is specifically designed for the treatment of idiopathic Parkinson's Disease. The drug is being developed by Supernus Pharmaceuticals under the name apomorphine infusion.